Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Current status of carbapenemases in Latin America
Indexado
WoS WOS:000323228200005
Scopus SCOPUS_ID:84880872131
DOI 10.1586/14787210.2013.811924
Año 2013
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Enterobacteriaceae and non fermenting Gram-negative bacilli have become a threat to public health, in part due to their resistance to multiple antibiotic classes, which ultimately have led to an increase in morbidity and mortality. -lactams are currently the mainstay for combating infections caused by these microorganisms, and -lactamases are the major mechanism of resistance to this class of antibiotics. Within the -lactamases, carbapenemases pose one of the gravest threats, as they compromise one of our most potent lines of defense, the carbapenems. Carbapenemases are being continuously identified worldwide; and in Latin America, numerous members of these enzymes have been reported. In this region, the high incidence of reports implies that carbapenemases have become a menace and that they are an issue that must be carefully studied and analyzed.

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Infectious Diseases
Pharmacology & Pharmacy
Microbiology
Scopus
Infectious Diseases
Virology
Microbiology
Microbiology (Medical)
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Maya, Juan J. Hombre CIDEIM Int Ctr Med Res & Training - Colombia
Centro Internacional de Entrenamiento e Investigaciones Médicas - Colombia
2 Ruiz, Sory J. - CIDEIM Int Ctr Med Res & Training - Colombia
Centro Internacional de Entrenamiento e Investigaciones Médicas - Colombia
3 Blanco, Victor M. Hombre CIDEIM Int Ctr Med Res & Training - Colombia
Centro Internacional de Entrenamiento e Investigaciones Médicas - Colombia
4 Gotuzzo, E. Hombre Hosp Nacl Cayetano Heredia - Perú
Hospital Nacional Cayetano Heredia - Perú
5 Guzman-Blanco, Manuel Hombre Hospital Vargas de Caracas y Centro Medico de Caracas - México
6 Labarca, Jaime Hombre Pontificia Universidad Católica de Chile - Chile
7 COSTA-SALLES, MAURO JOSE Hombre Santa Casa Sao Paulo Sch Med - Brasil
Santa Casa de São Paulo School of Medicine - Brasil
8 Quinn, John P. Hombre Astra Zeneca - Estados Unidos
AstraZeneca - Reino Unido
9 VILLEGAS-BOTERO, MARIA VIRGINIA Mujer CIDEIM Int Ctr Med Res & Training - Colombia
Centro Internacional de Entrenamiento e Investigaciones Médicas - Colombia

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
Novartis
Pfizer Inc.
Pfizer
AstraZeneca
Merck Sharp Dohme
Merck
Johnson Johnson
MSD Inc.
sanofi-aventis Inc.
AstraZeneca Colombia SA
Novartis Inc
United Medicals Brazil
Janssen-Cilag SA
Merck Colombia
Merck Sharp Dhome
BD
Pfizer SA

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
MV Villegas has received sponsorship for research by Merck Sharp & Dohme, Merck Colombia, Janssen-Cilag SA, Novartis, Pfizer SA and AstraZeneca Colombia SA. E Gotuzzo has been a consultant to Pfizer and has received research funds from Johnson & Johnson. M Guzman-Blanco is a member of advisory boards sponsored by Pfizer, Merck and BD. He has received research grants from AstraZeneca, Novartis. M Salles has received sponsorship for research by Novartis Inc, Pfizer Inc., MSD Inc., sanofi-aventis Inc. and United Medicals Brazil. J Labarca has been member of advisory boards for Merck Sharp & Dhome and Pfizer, has received research funds from Merck Sharp & Dhome, and has participated in clinical studies for Sanofi Pasteur. JP Quinn is an employee of AstraZeneca. JJ Maya, SJ Ruiz and VM Blanco report no conflicts of interests. None of the aforementioned companies funded or were involved in the elaboration of this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
MV Villegas has received sponsorship for research by Merck Sharp & Dohme, Merck Colombia, Janssen-Cilag SA, Novartis, Pfizer SA and AstraZeneca Colombia SA. E Gotuzzo has been a consultant to Pfizer and has received research funds from Johnson & Johnson. M Guzman-Blanco is a member of advisory boards sponsored by Pfizer, Merck and BD. He has received research grants from AstraZeneca, Novartis. M Salles has received sponsorship for research by Novartis Inc, Pfizer Inc., MSD Inc., sanofi-aventis Inc. and United Medicals Brazil. J Labarca has been member of advisory boards for Merck Sharp & Dhome and Pfizer, has received research funds from Merck Sharp & Dhome, and has participated in clinical studies for Sanofi Pasteur. JP Quinn is an employee of AstraZeneca. JJ Maya, SJ Ruiz and VM Blanco report no conflicts of interests. None of the aforementioned companies funded or were involved in the elaboration of this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Muestra la fuente de financiamiento declarada en la publicación.